E! 942, OxidoResist, HDxperts AB
| Reference number | |
| Coordinator | Biomotif AB |
| Funding from Vinnova | SEK 4 750 925 |
| Project duration | July 2022 - December 2025 |
| Status | Ongoing |
| Venture | Eurostars |
Important results from the project
Yes, all core project goals were reached. While strong resistance to LCTA2940 developed in fewer cell lines than initially expected, this provided important insight into the drug´s favorable resistance profile and did not limit the overall success of the project.
Expected long term effects
In the long term, the project may contribute to more durable, safer, and economically sustainable cancer therapies. The developed strategy offers a new way to address drug resistance without increasing toxicity, with potential impact on future drug development and clinical practice.
Approach and implementation
The project was executed through close collaboration between academic and industrial partners. Experimental work was conducted at Karolinska Institutet, while bioinformatic and machine-learning analyses were performed by geneXplain. Regular meetings ensured efficient coordination, data exchange, and integration of expertise.